Success Metrics

Clinical Success Rate
89.7%

Based on 26 completed trials

Completion Rate
90%(26/29)
Active Trials
1(3%)
Results Posted
31%(8 trials)
Terminated
3(8%)

Phase Distribution

Ph not_applicable
3
8%
Ph phase_4
6
16%
Ph phase_3
8
22%
Ph phase_2
7
19%
Ph phase_1
7
19%

Phase Distribution

7

Early Stage

7

Mid Stage

14

Late Stage

Phase Distribution31 total trials
Phase 1Safety & dosage
7(22.6%)
Phase 2Efficacy & side effects
7(22.6%)
Phase 3Large-scale testing
8(25.8%)
Phase 4Post-market surveillance
6(19.4%)
N/ANon-phased studies
3(9.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

86.7%

26 of 30 finished

Non-Completion Rate

13.3%

4 ended early

Currently Active

1

trials recruiting

Total Trials

37

all time

Status Distribution
Active(1)
Completed(26)
Terminated(4)
Other(6)

Detailed Status

Completed26
unknown6
Terminated3
Recruiting1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
37
Active
1
Success Rate
89.7%
Most Advanced
Phase 4

Trials by Phase

Phase 17 (22.6%)
Phase 27 (22.6%)
Phase 38 (25.8%)
Phase 46 (19.4%)
N/A3 (9.7%)

Trials by Status

recruiting13%
terminated38%
withdrawn13%
completed2670%
unknown616%

Recent Activity

Clinical Trials (37)

Showing 20 of 37 trialsScroll for more
NCT05217680Phase 3

Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema

Completed
NCT05439629Phase 3

Efficacy Evaluation Study of BAT5906 and Lucentis® in Patients With Macular Degeneration

Completed
NCT05304949

Regulatory PMS Study for Lucentis® in Patients With Retinopathy of Prematurity

Completed
NCT03362190Phase 2

ZIMURA in Combination With LUCENTIS in Patients With Neovascular Age Related Macular Degeneration (NVAMD)

Completed
NCT06305416Phase 3

A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema

Recruiting
NCT05003245Phase 3

Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD

Completed
NCT05571267Phase 2

Safety Study of Zimura in Combination With Anti-VEGF Therapy in Patients With Neovascular AMD

Terminated
NCT03927690Phase 2

Multiple Dose Safety and Efficacy of LKA651 in Patients With Diabetic Macular Edema

Completed
NCT04884399Phase 1

Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD

Completed
NCT01089517Phase 2

A Safety and Efficacy Study of E10030 (Anti-PDGF Pegylated Aptamer) Plus Lucentis for Neovascular Age-Related Macular Degeneration

Completed
NCT04667039Phase 3

Efficacy, Safety, pharmacokinetiсs, Immunogenicity of GNR-067 and Lucentis®

Unknown
NCT03097068Phase 4

Analysis of Cytokines in Response to Treatment of Diabetic Macular Edema With 0.3mg Lucentis

Completed
NCT05297292Phase 2

A Study to Evaluate the Efficacy and Safety of MW02 in the Treatment of nAMD

Unknown
NCT03211234Phase 2

Study Assessing the Efficacy and Safety of Intravitreal Injections of DE-122 in Combination With Lucentis® Compared to Lucentis® Monotherapy in Wet Age-related Macular Degeneration Subjects

Completed
NCT04857177Phase 3

A Study To Evaluate CKD-701 and Lucentis® in Patients With Neovascular(Wet) Age Related Macular Degeneration

Completed
NCT04847895

Observation of Treatment Patterns With Lucentis® in Real-life Conditions in All Approved Indications

Completed
NCT02834663Phase 4

Effects of Intravitreal Ranibizumab for Macular Edema With Nonproliferative Diabetic Retinopathy

Completed
NCT04063358Phase 3

Anti-VEGF Intravitreous Injections for Diabetic Macular Edema in Patients Undergoing Cataract Surgery

Unknown
NCT01170767Phase 3

French Evaluation Group Avastin Versus Lucentis

Completed
NCT03312283Phase 1

Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD

Completed

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
37